Pacira Pharma (PCRX) Misses Q2 EPS by 8c

Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of ($0.11), $0.08 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $70.9 million versus the consensus estimate of $73.6 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'
• BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c